Keyphrases
Solid Tumors
100%
Drug Resistance
100%
Hypoxia-activated Prodrug
100%
Erlotinib
66%
Evofosfamide
50%
Tumor Burden
33%
Tumor Control
33%
Clinical Trials
16%
Mathematical Modeling
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Tumor
16%
Monotherapy
16%
Treatment Strategy
16%
Tyrosine Kinase Inhibitor
16%
Treatment Efficacy
16%
Prodrug
16%
Cell Population
16%
Treatment Regimen
16%
Constraint-based Modeling
16%
Treatment Schedule
16%
Resistant Cells
16%
Survival Benefit
16%
Parametrized
16%
Treatment Delay
16%
Tumor Eradication
16%
Tumor Hypoxia
16%
Stochastic Mathematical Model
16%
Potential Therapeutic Strategies
16%
Therapeutic Effectiveness
16%
Cytotoxic Agents
16%
Hypoxic Zone
16%
Environmental Niche
16%
Help Design
16%
Cytostatic Agents
16%
Combination Toxicity
16%
Toxicity Constraints
16%
Drug Lead
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prodrug
100%
Solid Malignant Neoplasm
100%
Hypoxia
100%
Drug Resistance
100%
Neoplasm
85%
Erlotinib
57%
Evofosfamide
42%
Clinical Trial
14%
Non Small Cell Lung Cancer
14%
Protein Tyrosine Kinase Inhibitor
14%
Cytostatic Agent
14%
Epidermal Growth Factor Receptor
14%
Monotherapy
14%